2023 World Conference on Lung Cancer (Posters)-P2.05. MAPK1/MAPK3 Mutations Enhance Immunotherapy Efficacy in Lung Squamous Cell Carcinoma (LSCC): Results of the SQUINT Trial

P2.05. MAPK1/MAPK3 Mutations Enhance Immunotherapy Efficacy in Lung Squamous Cell Carcinoma (LSCC): Results of the SQUINT Trial - PDF(Slides)

Back to course

Pdf Summary

The SQUINT trial is a prospective randomized phase II trial that aimed to evaluate the efficacy of immunotherapy in untreated advanced Lung Squamous Cell Carcinoma (LSCC) patients. The trial compared the combination of nivolumab and ipilimumab (NI) with nivolumab plus platinum-based chemotherapy (N-CT). The results of an extensive biomarker analysis from the trial were reported.<br /><br />The study found that patients with mutations in MAPK1 or MAPK3 genes had significantly longer progression-free survival (PFS) and overall survival (OS) compared to those without these mutations. The median PFS was 8.4 months for MAPK1/3 patients compared to 4.0 months for MAPK1/3-negative patients. The median OS was 16.3 months for MAPK1/3 patients compared to 11.3 months for MAPK1/3-negative patients.<br /><br />Furthermore, the study also showed that patients with both MAPK1/3 mutations and high tumor mutational burden (TMB) had even longer PFS and OS. The median PFS for these patients was 9.1 months, and the median OS was 20.5 months.<br /><br />The findings suggest that mutations in the MAPK1/3 signaling pathway can predict better responses to immunotherapy in advanced LSCC patients. This provides a potential predictive biomarker for selecting patients who are likely to derive the most benefit from immunotherapy.<br /><br />Overall, this study contributes to the understanding of the molecular predictors of immunotherapy efficacy in LSCC and highlights the potential role of MAPK1/3 mutations as a biomarker for guiding treatment decisions in this patient population. Further research is needed to validate these findings and explore the underlying mechanisms of how MAPK1/3 mutations enhance immunotherapy efficacy.

Asset Subtitle

Gabriele Minuti

Meta Tag

Speaker Gabriele Minuti

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

SQUINT trial

immunotherapy

Lung Squamous Cell Carcinoma

MAPK1

MAPK3

progression-free survival

overall survival

tumor mutational burden

predictive biomarker

immunotherapy efficacy